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Abstract 
 
An increased attention has been drawn towards porous silicon (PSi) based materials for 
biomedical applications, due to their promising features demonstrated through several 
scientific studies. Here, we further investigated the biological responses of PSi 
nanoparticles (NPs) with different surface chemistries, including immunomodulatory 
effects, inflammation mitigation and biocompatibility. In this collaborative study, the PSi 
NPs were investigated both in vitro and in vivo, using different molecular biology and 
biochemistry techniques, e.g., qPCR, ELISA, cell sorting and cell viability assays. Our 
results showed the capabilities of these PSi NPs to relieve the inflammatory conditions, 
whereas significant decrease was recorded of pro-inflammatory cytokines: TNF-α, IL-1β 
and IL-6. Likewise, these PSi NPs revealed a considerable consumption aptitude of pro-
inflammatory reactive oxygen species molecules. Administrating PSi NPs in an acute 
liver inflammation (ALI) model, showed no conspicuous influence on cellular viability. 
Thus, the outcome of this study demonstrates the potential biocompatibility of PSi 
nanomaterials, in addition to their outstanding features as potential candidates for further 
incorporating in ALI applications.  
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1. Introduction  
 
Nanotechnology can be defined as an efficient approach to control and manipulate 
materials at a nanoscale, whereas it has been found that the matter tends to exhibit 
different properties at scale of 1 to 100 nanometers, namely “nanomaterial”. 
Nanomaterials are identified as particles having at least one dimension of  100 nm. In 
Figure 1 [1], this size range is exhibited comparing to other different objects.   
 
There are several physicochemical characteristics that favor nanomaterials over macro 
materials, for example, high surface-to-volume ratio that exponentially escalate the 
chemical reactivity of the nanomaterial in spite of their small volume, and the enormous 
surface area of these nanomaterials can be functionalized with different small molecules, 
metal ions, polymers and surfactants [2]. Owing to the nanoscale size and high surface 
area, these materials exhibit exceptional chemical and physical features, which make 
them suitable agents for developing expedient nanodevices that can be used in several 
biomedical, biological, physical and chemical applications.  
 
For instance, nanoparticles (NPs) have demonstrated an exceptional ability to deliver 
drugs within ideal dosage, leading to more efficient therapeutic effect and less side-effects 
[3]. Furthermore, due to their optical properties, nanoparticles are being employed in 
imaging techniques for visualizing cellular and other biological specimens [4]. Also, 
many of semiconductor and metallic NPs exhibit promising features for cancer diagnosis 
and treatment depending on their surface plasmon resonance (SPR) enhanced light 
scattering and absorption. Au NPs are strong example of this, whereas, they are able to 
transform the absorbed light into confined heat that can be employed in selective laser 
photothermal therapy of cancer. Likewise, conjugation of Au NPs ligands precisely 
targeted to biomarkers on cancer cells, allowing for molecular-specific imagining and 
identification of cancer cells [5]. 
 
NPs also possess an antineoplastic effect that is exploited to inhibit tumor growth, as 
shown by Chen et al. [6], using multihydroxylated [Gd@C82(OH)22]n NPs that showed 
potential efficacy and minor toxicity. NPs are involved in many other sectors, including 
water disinfecting, textiles and food packing, especially owing to the antimicrobial 
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features of inorganic NPs comparing to organic compounds, which were found to be more 
toxic to the biological entities [7]. Similarly, Ag NPs are being used in wound bondages, 
catheters and other various products due to their antimicrobial properties [8]. Other NPs 
also are known for their antibacterial activities, including; TiO, ZnO, BiVO4, Cu and Ni 
NPs, thus they are utilized for similar applications [9-12].  
 
In other industries, NPs are also of high demand, because they can exhibit the potential 
catalytic properties. Thus they are introduced, for example, to accelerate some oxidation-
reduction processes of some pollutants [13]. 
 
Due to these unusual characteristics, NPs are considered an essential tool of high demand 
in nanotechnology industry in addition to attract a great attention in scientific research in 
many sectors, including biomedicine, cosmetics, bioremediation, material sciences, 
electronics and food packing [14, 15]. Nowadays, there are more than 1500 
nanotechnology-based products in the market, widely distributed among different fields, 
starting from toilets slates and hydrophobic self-cleaning surfaces to strengthened tires 
containing carbon nanotubes [16].  
 
1.1. Brief history  
 
Although nanotechnology is one of the leading technologies in the current age, it is not a 
latter-day innovation. Nanomaterials have been used since very long time ago [17]. The 
Lycurgus Cup from the 4th century is an example of this early technology, which has been 
found to contain NPs of Ag and Au reflecting the light, giving the cup green color when 
lit from outside, and red color when lit from inside it looks red, as shown in Figures 1B 
and 1C [18].  
 
Nevertheless, in the present time the nanotechnology term and the microscopic 
instrumentation were first presented in 1959 by the Nobel-winning physicist Richard 
Feynman, whereas he mentioned “There’s plenty of room at the bottom” in his speech in 
California Institute of Technology. In his talk, Feynman cited a friend’s suggestion: 
“(Albert R. Hibbs) suggests a very interesting possibility for relatively small machines, 
saying”, although it is a very wild idea, it would be interesting in surgery if you could 
swallow the surgeon. You put the mechanical surgeon inside the blood vessel, and it goes 
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into the heart and "looks" around. (Of course, the information has to be fed out.) It finds 
out which valve is the faulty one and takes a little knife and slices it out. Other small 
machines might be permanently incorporated in the body to assist some inadequately-
functioning organ.” [19].  
 
Later in 1986, the notion of cell repair machines has been proposed by Eric Drexler, in 
his book “Engines of Creation”. He suggested these machines to efficiently and precisely 
repair the cellular damage within different levels, starting from the cellular structures and 
organelles to the DNA level. Later in 1996, dazzling array of conceptual diamondoid 
nanomedical components and nanorobots was emphasized by Robert Freitas in his first 
book of “Nanomedicine” series [16]. Since then the nanoscale functionalized particles 
have been enormously spreading around.    
 
1.2. Nanomaterials in medicine 
 
Nanotechnology principles are vastly applied in medicine, which created what’s called 
“nanomedicine” field, referred by National Institutes of Health (NIH) [20]. In 
nanomedicine, diseases are handled at molecular and cellular levels, which makes it more 
manageable to trace where and how diseases originate. For instance, there are intensive 
investigations on the therapies that can manipulate the patients’ own genes or modify 
some signaling pathways involved in diseases, towards finding an efficient treatment. 
Thus, in the near future researchers may be able to exhibit the whole DNA strands and 
execute some necessary repairing modifications through, for example, some nanorobots 
able to perform inside the cellular environment. Another interesting example still under 
development, is the in-situ nano-factories, which are composed of self-assembly 
components designed to be able to build the protein-based drugs at the targeted site, rather 
than the complicated delivery process during which the drug is usually decomposed by 
the body mechanisms.  
 
Currently, there are many developed nanotechnologies already available, such as Au 
nanoshells, which are used within cancer therapy and bioimaging, and superparamagnetic 
iron oxide NPs (SPIONs), which are used to trace and damage cancer cells thermally, 
avoiding damaging the surrounding healthy cells “hyperthermia”. Another interesting 
invention is the hollow nanocarriers, e.g., liposomes which can be employed as carriers 
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to deliver anticancer drugs and other medication to the targeted diseased cells [16]. All 
of these technologies are proving nanomedicine as a promising alternative for the 
ordinary medical approaches, e.g., chemotherapeutic medications that are considered 
toxic regarding to their unpleasant side effects.   
 
 
 
1.3. Classification of NPs and their potential biomedical applications  
 
Several nanomaterials have been utilized for decades, e.g., in glass crafting, and paintings, 
on the other hand, there are many other new discovered nanomaterials involved in variant 
fields, e.g., in cosmetics, sports products and pyrotechnics (fireworks chemistry) [21]. 
Furthermore, there are also other applications under research, e.g., medical implants, drug 
delivery, biodetectors, solar cells and fuel cell [22, 23]. 
 
The last decade has witnessed a hug increase in nanotechnology products (Figure 2a) [1]. 
However, it is worth mentioning that these products are mainly targeting health and 
fitness issues (Figure 2b) [1]. Nevertheless, NPs have been employed for many other 
applications, e.g., environmental: bioremediation; accelerating the growth of some plants, 
and industrial: heat transfer; food manufacturing; personal care products; construction 
Figure 1:  
(A) Size range of nanoparticles (10-1–102 nm) comparing to other objects. 
(B-C) The Lycurgus Cup from the 4th century is an early nanotechnology-based example, which has been 
found to contain nanoparticles of Ag and Au. The pictures exhibit the fascinating phenomena about this 
Lycurgus cup, caused by the lights reflection manner, whereas, the cup appears green when is lit from 
outside (B), while it looks red when it is lit from inside (C) [18]. 
(Reference: López-Serrano, A., et al., Nanoparticles: a global vision. Characterization, separation, and quantification methods. 
Potential environmental and health impact. Analytical Methods, 2014. 6(1): p. 38-56.)  
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supplies. However, in this study, we mainly discuss the biomedical applications of 
nanotechnology [1]. 
 
NPs are widely utilized within various biological applications, for example, biological 
markers due to their protein-like size range and their fluorescence features, e.g., quantum 
dots. Furthermore, NPs compose the core of several nano-biomaterials are capable of 
interacting with biological objects within non-covalent interactions. Considerably, the 
approaches applied to build this nano-biomaterials are determined by the properties of 
those NPs, e.g., their nature, biocompatibility, shape recognition, antigen detection, 
fluorescence monitoring [1, 24].  
 
There are other microbiology related applications since NPs can be employed to detect 
bacterial existence, for example, CdS NP tracers are used through conjugating with 
specific bacteria to form a combination that permits DNA hybridization detection within 
immunological assays [24, 25]. Drug and gene delivery are other fields where NPs are 
also being employed. Incorporating drugs and genes within NPs provides protection 
against degradation and increase the cellular uptake [26, 27]. NPs are also used for protein 
ultrasensitive electrochemical detection, through nano-sizes biosensors, possessing 
significant versatility in addition to distinctive electrochemical features [28].  
 
Likewise, quantum dots NPs are employed for fast and sensitive recognition of prostate 
specific antigen (PSA) within human serum with detection threshold of 20 pg/mL [29]. 
Additionally, DNA structure can be projected through establishing DNA conjugates, 
utilizing the distinctive optical and electronic features of those quantum dots NPs. Thus, 
these Au NPs are capable of differentiating between target-free and target-bound 
oligonucleotides through SPR [30], or alternatively,  they are able to identify the target-
responsive structural variations of DNA [31]. Also, NPs were found to be useful for 
microbial examining and detection, which may replace the in vitro and in vivo identifying 
of the target molecules. Therefore, sensors made of iron oxide have demonstrated 
significant sensitivity towards quantification of certain biomolecules within cell lysates 
and tissue extracts [32].  
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Currently, markets have witnessed a remarkable growth of using NPs for medical 
applications, e.g., diagnosis, drug delivery and imaging [33]. This is a result of a 
continuous research and development of micro- and nano-technology, which have 
introduced remarkable amount of new and cutting-edge techniques for either synthesis or 
functionalization of these nanomaterials.  
 
 
 
NPs can be categorized on variant considerations, e.g., the origin (natural or 
anthropogenic), chemical structure (organic or inorganic), size, form and surface features, 
in addition to their applications.    
 
 
Figure 2: Products based on nanotechnology and the continuous growth over the last few years, whereas by 
2010, nanotechnology-based products were estimated about 1300 (a), and  main categories of these nanotech 
products are demonstrated in figure (b) showing a huge great in health and fitness sector.  
 
Reference: 
http://www.nanotechproyect.org/inventories/consumer. 
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 Nanoparticles classified according to the chemical structure 
 
 Carbon-based nanomaterials 
 
This category of nanomaterials is composed of pure carbon and it is categorized in two 
main sets: 1. Fullerene: which is mainly a particle comprised of 60 carbon atoms at least; 
and 2. carbo nanotubes (CNTs).  
 
The most popular form of Fullerene is C-60, also called “buckminsterfullerene”, and it is  
spherical carbon molecule in which the atoms are usually organized in truncated 
icosahedron construct [34]. Nevertheless, there are other less stable fullerene structures, 
e.g., C70, C76, C78, and C80 (Figure 3a) [35], which are utilized in different medical 
approaches. For instance, fullerenes have been found to possess an antiviral effect, in 
addition to their ability to penetrate and create connections in the catalytic sites of some 
enzymes. Thus, fullerenes were able to inhibit an HIV protease, which is critical for the 
survival of the virus. This reaction has been explained owing to the strong van der Waals 
interaction between the fullerene and the hollow surface of the enzyme [36].   
 
CNTs occur in different types with different characteristics, fabricated in diverse 
techniques. Owing to their advantageous electrical, chemical and mechanical features 
they are of high demand in many fields, including medicine and biochemical industries 
[37]. CNTs can be used in eliminating many elements, for instance, pathogens, some 
natural organic substances and cyanobacterial toxins from water because of their extreme 
adsorption capability. CNTs have fibrous structure and huge external surface area 
(Figure 3b) [38], which is simply accessible by biological compounds/toxins [39].  
 
 Metal oxide NPs 
 
This category of NPs comprises various transient metal oxides, e.g., ZnO, TiO2, CuO and 
SiO2. Due to the special features of this elements, in addition to the remarkable reactivity 
feature of NPs, these NPs are used in many diverse industries, as catalysts and in medicine 
[40, 41]. For example, iron oxide NPs are commonly employed within many in vivo 
approaches due to their magnificent superparamagnetic features, e.g., tissue repair, 
immunoassays, drug delivery, magnetic resonance imaging contrast enhancement and 
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detoxification of biological fluids [42]. Likewise, silicon (Si) NPs are important group in 
this category and they are utilized in various biomedical approaches, e.g., drug delivery. 
However, we will discuss their properties later in this thesis.  
 
 Quantum dots (QDs) 
 
These particles are auto-fluorescent semiconductors nanocrystals that are vastly used in 
in vivo imaging [24, 43-45], owing to their quantum incarceration feature. Moreover, QDs 
exhibit an interesting optical feature, for instance, sharp and symmetrical emission 
spectra, high photo steadiness and extreme quantum revenue. The most common 
structures of these QDs are binary metal complexes, e.g., CdS, CdZn and CdSe, which 
are extensively applied in biological labelling within many sorts of animal cells. 
However, there are other forms of QDs created by amalgamation, for example, CdSe-ZnS 
core-shell nanocrystals, which are used as bioactive fluorescent probes for imaging, 
sensing, immunoassays and else diagnostic approaches.  
 
 Elemental metallic NPs 
 
This group of NPs comprises inorganic NPs that are primarily constituted of noble 
elements, e.g., Au and Ag, combined with other transition metals, e.g., Fe and Zn. These 
particles are involved in many applications, such as, bioremediation and biomolecules 
detection. Ag NPs possess an exceptional antimicrobial feature, whereas the close contact 
between the silver nuclei and the cell wall, cause its interruption [46-49]. Also, gold NPs 
have lately acquired a big importance due to their conjugation possibility with the 
biomolecules across their function groups and act chemically as an anchor and element 
markers, thus they are widely used as element tags in proteomics [50].  
 
 Organic polymers 
 
These are composed of organic polymers that are extremely stable upon contact with 
biological fluids. Thus, their polymeric features are of high potential for pharmaceutical 
purpose, e.g., controlled and sustainable drug release. It has been shown in previous 
neurological studies that some of these biodegradable polymerics materials with specific 
surface adjustment were capable of delivering drug beyond the blood brain barrier in 
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favor of diagnostic and therapeutic approaches [51]. Additionally, due to the high 
capacity they have shown, upon modifying or imprinting, they are being applied to 
recognize and bind to targeted chemical compounds, in addition to some analytical 
approaches, e.g., solid phase extraction and clinical analysis. For example, artificial 
antibodies with high selectivity and sensitivity were  developed by molecularly imprinted 
polymeric NPs synthesized for human rhinovirus immunoglobulins [52]. Table 1 
summarizes the different types NPs and their common biomedical applications. 
 
 
 
 
Table 1. Classification and main biomedical applications of nanoparticles [1]. 
Figure 3: (a) Different forms of Carbon-based nanomaterials, including Fullerenes (C60, C70, C76, C78-
C2V, C78-D3, C84-D2 and C84-D2d, in addition to (b) nanotube form.  
 
 
(Reference for this model: (a) Louazri, L., et al., Study of the Effect of Substitution on Phtalocyanine Based Compounds for 
Photovoltaic Application. International Journal of Chemistry and Materials Research, 2015. 3: p. 65-78. 
(b) Segawa, Y., H. Ito, and K. Itami, Structurally uniform and atomically precise carbon nanostructures. Nature Reviews Materials, 
2016. 1: p. 15002. 
 
Nanoparticle 
Chemical 
composition Principle of application References 
CNTs Pure carbon Diagnostic and sensing element to detect and monitor 
several diseases, especially diabetes but also bacterial 
infection. 
[53] 
Selective reactivity with certain biomolecules. [39] 
 
Fullerenes 
 
Pure carbon 
 
Selective reactivity for antiviral activity. 
 
[36, 37]  
 
Metal oxides 
ZnO Excellent biocompatibility. 
Anticancer and antibacterial agent. 
[54] 
Silica Drugs and gene delivery. [55] 
TiO2 Photodynamic therapy and delivery of different anticancer 
drugs. 
[56] 
TiO2 Positive effects on strength and growth of plants. [57]  
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(Reference: López-Serrano, A., et al., Nanoparticles: a global vision. Characterization, separation, and quantification methods. 
Potential environmental and health impact. Analytical Methods, 2014. 6(1): p. 38-56.)  
 
 
1.4. Immunogenicity and biocompatibility of nanomaterials 
 
 Biodistribution and stability of NPs in the biological environment 
 
The biodistribution of the inorganic NPs, within the in vivo biological environment, has 
been intensively investigated, including quantum dots and superparamagnetic NPs. The 
bare inorganic core of NPs will not be stable within the biological conditions; therefore, 
it always occurs within organic coating, either chemically designed during developing 
the NPs or obtained by the adsorbed surrounding proteins [69, 70] (Figure 4). Otherwise, 
without the organic coating, the plain NPs tend to aggregate [71].  
 
Theoretically, the ideal NP is defined as hybrid entity of three parts: inorganic core, 
surface coating and external adsorbed compounds from the surrounding biological 
CeO Enzyme mimetic and reactive oxygen species (ROS) 
scavenging activities. 
[58] 
CuO  
 
Al2O3 
Antimicrobial agents. 
Oral drug delivery, biosensing, cancer therapy and 
anticancer properties. 
[59] 
 
[60] 
MnO2, ZrO2 Antibacterial and anti-inflammatory features. [61] 
Iron oxides Antimicrobial activity, magnetic hyperthermia 
(superparamagnetic properties). 
[62, 63] 
Medical diagnosis: Sensors for microbial detection. [32] 
    
Quantum dots 
(QDs) 
CdSe Medical diagnosis: Luminescence properties for labelling 
bacteria. 
[52]  
CdS Biomedical imaging: Biomarkers. [24, 42-44]  
CdSe/ZnS Biomedical imaging: Bioactive fluorescence; 
immunoassay applications.  
[25, 52]  
Metallic NPs Ag Antimicrobial properties. [45-48]  
Localized surface plasmon resonance. [45-48]  
Antibacterial activity. [64] 
Au Surface plasmon resonance. [30, 31, 65]  
Au Conjugation with biomolecules.  [66, 67]  
Polymers Alginate/chitosan Slow drug delivery. [51]  
Encapsulated, adsorbed or dispersed bioactive compounds 
maintaining their structure, activity and releasing over a 
longer time. 
[68]  
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environment. However, in this study we did not investigate the outer layers coating of the 
inorganic core.  
 
The identity of the NP is described according to the nature of its core, which defines its 
physical features, e.g., superparamagnetic or fluorescent [72]. Therefore, the core is 
responsible for many vital approaches, such as exhibiting the contrast within imaging and 
detection techniques or rising heat by excitement within hyperthermia procedures. 
However, maintaining the physical properties of the core within the biological 
environment is essential, especially within theranostic approaches. Therefore, 
biotransformation occurring to NPs, e.g., degradation or aggregation, may imperil those 
physical properties according to the surrounding environment.  
 
Previous studies have shown that semiconductor Si is an ideal model to be employed as 
core biomaterial owing to its promising features, since it can occur in several 
biocompatible designs, in addition to its competence to bind to living tissues. Furthermore 
it was demonstrated to be fully biodegradable [73]. 
 
The surface coating plays also a critical role to define the physicochemical properties of 
the NPs, known as “synthetic identity” [74]. The surface coating can be of different kinds 
of molecules, e.g., lipolic acids, peptides or silica shells [75, 76]. The subsequent 
physicochemical properties of NP, e.g., hydrophobicity and surface charge determine its 
colloidal stability. Therefore, proper NPs surface coatings should tackle agglomerations 
of NPs and enhance dispersion in the surrounding environments. And achieving this 
depends on many factors within biological environments, e.g., which molecules adsorb 
to the surface, cellular uptake and even cell viability.  
 
Within the biological environments, some degree of in-situ biotransformation has to 
occur for most of NPs, i.e., adsorption of the surrounding molecules on the surface of NPs 
forming what is known as ”biomolecule corona”, of which protein corona (PC) has been 
widely investigated, which is now well recognized, but still not well understood [69, 77-
82]. 
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 Cellular interaction and bio-fate of NPs 
 
It has been shown in several cell based studies how cells react with NPs during 
administration, whereas most of mammalian cells have shown different capacities to 
incorporate NPs, owing to different nonspecific uptake mechanisms [83]. Nevertheless, 
under in vivo circumstances, some mammalian cells are capable of significantly 
degrading those NPs. The interactions occurring in vivo between close tissues, lead 
certain cells to break down any foreign particles, e.g., NPs. For instance, the macrophages 
within the mononuclear phagocyte system (MPS) are known to possess high potency to 
clear and process large NPs from the blood stream, whereas, most of the other cells are 
lacking the sufficient capacity to incorporate and process the NPs. However, it is worth 
mentioning, that within in vivo conditions, the clearance of NPs vastly alters, according 
to the status of the immune system [84]. Subsequently, degradation of NPs under in vivo 
conditions, is highly dependent on many factors, such as the physicochemical properties 
Figure 4: Illustration of an inorganic NP within in vivo biological environment composed of inorganic core 
(black circle), enveloped by organic coating (grey color) which assists the colloidal stability and an outer layer 
of adsorbed proteins (blue color), within the in vivo circumstances, NPs tend to change their physicochemical 
features, including dynamic altering of the protein corona, according to the changes in the biological 
surrounding conditions or the mechanisms of cellular degradation that may even degrade the NP into tinier 
individual fragments. Moreover, some inorganic cores might decompose, and thus, alter the physical and 
morphology. Likewise, the organic coating can be partially detached while the adsorbed proteins are being 
degraded.   
 
(Reference: Feliu, N., et al., In vivo degeneration and the fate of inorganic nanoparticles. Chemical Society Reviews, 2016. 45(9): p. 
2440-2457.) 
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of the NPs and the type of the cell exposed to the NPs, which can also determine the 
biodistribution and intracellular transfer of the NPs.  
 
NPs based biomedicines are commonly introduced as bolus injection intravenously. Next, 
the blood stream carries the NPs to the right chamber of the heart, then to the lung, back 
to the left heart chamber then to the arterial system distributing the NPs to different 
organs. During this transporting process, a large blood portion arrives to the liver and 
spleen, which possess high potency to filtrate the blood and eliminate xenobiotic particles, 
e.g., NPs. Several quantifications experiments have estimated distributions of labelled 
NPs and they found that huge portion of protein coated NPs were incorporated and 
trapped by these organs [85, 86]. Endothelial cells are as well a secondary adequate 
receiver of those NPs in vivo. Since, these endothelial cells are lining the blood vessels 
around the body they got in direct contact with the administrated NPs [87]. Figure 5 [71] 
shows an overview of the whole uptake process, collected from different articles [85, 88-
90]. 
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Figure 5: Fe-labeled FeOx NPs were injected in mice intravenously and their distribution and 
degradation were monitored. These NPs exhibited a 25 nm diameter, carrying surface negative charge 
and composed of monodisperse iron oxide core with 11 nm diameter, coated with amphiphilic 
polymer, poly(maleic anhydride-alt-1-octadecene). Liver cells, i.e., Kupffer cells and liver sinusoidal 
endothelial cells (LSECs), were detected incorporating large portion of the NPs within minutes. 
Furthermore, the degradation of the FeOx core was estimated by measuring the amount of Fe 
presented in the hemoglobin of the lately produced red blood corpuscles. Nevertheless, peripheral 
vascular endothelial cells (PVECs), are another reservoir to receive FeOx NPs.  
However, the outcome of monitoring the degradation of FeOx NPs, exhibited a notably degradation 
efficacy difference among the different sorts of cells, proposing that the NPs undegraded residues are 
possibly remaining in the cells causing a cell specific long-term toxicity. 
 
MPS = mononuclear phagocyte system (mainly liver and spleen).  
 
(Reference: Feliu, N., et al., In vivo degeneration and the fate of inorganic nanoparticles. Chemical Society Reviews, 2016. 45(9): 
p. 2440-2457.) 
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 Immune response to NPs 
 
Nanotechnology based drug delivery systems may be designed to recognize a biomarker 
in certain tissues of a specific patient. However, these systems are susceptible to be 
recognized and targeted by the immune system as an outsider body. Even though, there 
are several studies have been conducted to understand these immune responses, it is still 
challenging to have a clear interpretation, because the immune responses vary intensively 
between different lab animals and humans, which makes the immune response in human 
bodies difficult to predict [91].  
 
There is a study conducted by Bremer-Hoffmann and Halamoda-Kenzaoui et al. [91] 
from the European Commission Joint Research Centre (JRC), Ispra (VA), Italy, that 
reviews different scientific literature and concludes the most recurrent in vivo immune 
response induced by different nanomaterials are inorganic NPs, lipid-based and polymer-
based NPs (Figure 6A) [91], of which, inorganic NPs were found to be responsible for 
~68% of the explained immune reactions. The results showed that approximately 50% of 
the examined NPs provoked reactions that triggered immune response. The most 
immediate immune response occurs upon intravenously administration. Prompting the 
immune reactions can be favorable to the host animal because it can assist recognizing 
and removal of any harmful invasive materials. Some NPs based trails have shown 
noticeable positive medical effects, for instance, Au nanorods have exhibited suppressing 
effect on respiratory syncytial virus and also stimulating an antiviral reactions in mice 
models [92].  
 
Human immune system adopts two main defense mechanisms: innate immune and 
adaptive immune mechanisms. Under microbial attack, the innate system provokes 
nonspecific reactions to tackle the microbial invasion, however, the adaptive system joins 
later with more specific reactions, including stimulating the lymphocytes and 
synthesizing consequent antibodies. It is worth mentioning, NPs were exhibited immune 
reactions to both innate and adaptive immune systems, either provoking or quelling 
(Figure 6B) [91]. Moreover, the immune responses are highly dependent on structure of 
the NPs protein corona layer. 
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In Figure 7 [91], the most reoccurring NPs-based immune responses were described, in 
corresponding to NPs groups. In conclusion, 61% of the articles describing lipid-based 
NPs immune effects, mentioned that the main effects are activating the complement 
system, complement activation-related pseudoallergy (CARPA), in addition to activating 
the adaptive immune system. On the other hand, ~65% of evaluated polymer-based NPs 
were identified as immune friendly and did not exhibit any potential immunotoxicity. 
However, these polymer-based NPs were commonly provoking an antigenicity response 
convoyed by releasing of specific antibodies, in signaling cascades lead to accelerated 
blood clearance (ABC) of those nano compounds. Lastly, 70% of the examined inorganic 
NPs showed a negative effect on the immune systems, especially, an escalated threat of 
inflammation accompanied by innate or adaptive immune response.   
 
 
 
 
 
 
Figure 6: (A) The outcome of the reviewed in vivo studies showing the main NPs to provoke 
immune responses, whereas inorganic NPs was the major group with an approximate 
percentage of 68%. (B) The main various immune responses provoked by NPs, showing 
immunoactivation to be the major immune response. 
 
(Reference: Halamoda-Kenzaoui, B. and S. Bremer-Hoffmann, Main trends of immune effects triggered by nanomedicines in 
preclinical studies. International journal of nanomedicine, 2018. 13: p. 5419-5431.) 
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Among 108 literatures within this study (Hoffmann and Kenzaoui) reporting immune 
activation reactions by NPs, 43 described the inflammatory procedures to comprise 
proinflammatory cytokines production and inflammatory histological changes (Figure 8) 
[91]. Nevertheless, the NPs-induced inflammation mechanisms were concluded to occur 
in main forms, including oxidative stress initiation, toll-like receptors recognition, which 
is responsible for pathogen identification, and activating corresponding inflammatory 
pathways, e.g., cellular nuclear factor-κB. Mainly, the inflammatory responses were 
attributed to inorganic NPs, primarily silica NPs [93], carbon/metal based NPs , Au NPs 
[94, 95] and graphene oxide-based nanomaterials [96, 97]. 
 
 
 
 
 
Figure 7: The figurers illustrate the most common in vivo NP-induced immune responses, categorized 
based on the nature of the NPs. Nevertheless, the type of immune responses depended on the nature of the 
NPs. Thus, polymer-based NPs exhibited the most immune friendly effect, meanwhile inorganic NPs were 
the least friendly with several immune responses, mainly inflammation. Lipid-based NPs provoked several 
immune responses, including complement activation-related pseudoallergy (CAPRA) and adaptive 
immune response. 
 
(Reference: Halamoda-Kenzaoui, B. and S. Bremer-Hoffmann, Main trends of immune effects triggered by nanomedicines in 
preclinical studies. International journal of nanomedicine, 2018. 13: p. 5419-5431.) 
 
Figure 8: Based on the reviewed literatures, the 
most reported NPs-based immune response 
happening in high reoccurrence.  
 
CARPA = complement activation related 
pseudoallergy.  
 
(Reference: Halamoda-Kenzaoui, B. and S. Bremer-
Hoffmann, Main trends of immune effects triggered by 
nanomedicines in preclinical studies. International journal 
of nanomedicine, 2018. 13: p. 5419-5431. 
  18 
 Role of inflammatory response in liver diseases and oxidative stress 
 
Inflammation is considered as potential sign indicating existence of harm conditions or 
organisms, and it can even refer to cancer development when paired with tumorigenesis 
[98]. Pathogenic microorganisms are detected through a key signaling platforms called 
“inflammasomes”, which are also responsible for activating the corresponding 
inflammatory response.  
 
Hepatic tissue damage is attributed mainly to hepatic inflammation, which is also 
considered as common provoker of liver diseases [98]. Under hepatic inflammation 
conditions, liver experiences progression from nonalcoholic fatty liver disease (NAFLD), 
which is defined as an accumulation of fats, approximately  >5%, in liver cells for a reason 
else than excessive alcohol consumption [99], to fibrogenesis and ultimately 
hepatocellular carcinoma (HCC).  
 
Oxidative stress and lipid peroxidation are strong consequences of the liver inflammation 
and damaged liver, which frequently trigger characteristic histological lesions of  NAFLD 
[100, 101]. Under liver inflammatory circumstances, the inflammatory cells and the 
hepatocytes discharge cytokines, e.g., tumor necrosis factor alpha (TNF-α) and reactive 
ROS, which can prompt peroxidation of plasma and mitochondrial membranes, leading 
to cellular death owing to necrosis and apoptosis [100, 101].  
 
As mentioned earlier, liver represents an ultimate harbor for the intravenous 
administrated NPs, where NPs are incorporated and trapped though blood filtration 
process. Consequently, it is worth studying the inflammatory response and effect of those 
NPs on the liver.  
 
Therefore, in this work we aimed to investigate the immunomodulatory and biological 
effects of a widely used inorganic NPs, such as porous silicon (PSi) NPs, on liver 
functions. 
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1.5. Nanomedicine today and future aspects 
 
There is a very rapidly growing number of applications within the nanomedicine field, 
including drug delivery, thermal assays, e.g., hyperthermia, and imaging. Moreover, in 
medical diagnostics, nanotechnology is contributing a huge advance, as these require an 
accurate identification of the targets, e.g., tissues, cells and receptors, that correspond to 
certain medical disorder, thus designing the perfect matching NPs, which accomplish the 
required reaction with the least side effect [20].   
 
Nanomedicine represents promising tools to transform the increasing medical discoveries 
into practical treatment for patients, including these NPs that mimic the biological system, 
e.g., those that are efficient in early diagnosis and cancer targeted drug delivery therapies.  
 
Likewise, there are verities of fascinating rising effective technologies for targeting 
diverse cell types within the body optimizing the delivery of cargo, e.g., drugs, genetic 
materials, diagnostic elements or any else medical therapies. Thus, currently, drug 
delivery and diagnostic assays are the leading projects within the nanomedicine field.  
 
1.6. Porous silicon nanoparticles (PSi NPs) 
 
Electrochemical etched PSi has attracted attention for various biological applications due 
to its exceptional features, e.g., biocompatibility [102], biodegradability [103] and 
tunable porous nanostructure [104], which is highly advantageous for drug delivery 
approaches.  
 
In 1956, porous silicon (PSi) was discovered by Uhlir accidently, when he was 
conducting some electropolishing studies on Si wafers with hydrofluoric acid. During his 
experiments he discovered that under certain circumstances of suitable current and 
solution constitution, the Si did not dissolve homogeneously, and fine holes were formed 
instead. Subsequently, Si wafers were utilized to produce PSi, by electrochemical 
dissolution of the Si wafers in aqueous or ethanoic hydrofluoric acid solutions [105]. 
Since then there was no much attention drawn towards PSi, until 1995 when PSi was 
verified by Canham to be biocompatible and biodegradable [103].  
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After that, PSi was under intensive investigated in biomedical applications, owing to its 
unique features: (1) high porosity / large pore volume (up to 80% / ≈ 0.5–2.0 cm3/g) which 
is perfect for high loading degree; (2) adjustable surface chemistry and enormous surface 
area (up to 580 m2/g), this surface can be functionalized for several biological functions 
like controlling drug release [104, 106]; (3) modifiable pore size (≈ 5 – 150 nm) to load 
various molecules, including macro- ,small- and NPs [107, 108].  
 
Moreover, PSi is promising for drug delivery and other biomedical applications, e.g., 
bioimaging, tissue engineering and immunotherapy applications [109]. Another 
advantage of utilizing PSi is its great biocompatibility since it can be completely degraded 
to nontoxic orthosilicic acid [Si(OH)4], which is naturally occurs in the human body [103, 
110, 111]. 
 
 Fabrication of PSi 
 
Commonly, PSi is synthesized by electrochemical anodization of monocrystalline Si 
wafers in a hydrofluoric acid electrolyte solution. Furthermore, the porosity and pore size 
can be modified through manipulating the manufacturing parameters, thus the 
biodegradability of a PSi structure can controlled accordingly with its the pore size and 
porosity [109]. Therefore, PSi has been found of  great advantage in drug delivery 
applications, whereas, the pore sizes can be adjusted according to the properties of the 
loaded drug and the release mechanism [104].  
 
There are different forms of PSi being utilized in biomedicine, according to the purpose. 
However, the spherical shaped (quasi) PSi micro- and nanoparticles are the most 
abundant form within drug delivery systems, owing to their broad selections and being 
easy to produce. In the following section, the fabrication process of spherical shaped 
(quasi) PSi is described.  
 
 Fabrication of spherical shaped (quasi) PSi 
 
The technology of engineering PSi micro- and nanoparticles has developed remarkably 
recently, and those produced PSi particles have attracted much attention. PSi is described 
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as nanostructured material manufactured frequently through etching single-crystal Si 
wafers [109]. As mentioned earlier, PSi is commonly produced in top-down approach 
through electrochemical anodization of monocrystalline Si wafers in a hydrofluoric acid 
electrolyte solution. After the anodization process, a PSi film is separated from the Si 
wafers as whole thin chips (Figure 9a) [109]. Afterwards, comes the comminution step, 
and it can be accomplished  through different approaches, e.g., ultrasonication [112], high 
pressure micro-fluidization [113] or milling [114]. Ultimately, the outcome is PSi 
spherical shaped particles (quasi).  
 
During the PSi NPs fabrication procedure, there are main principles to consider: (1) 
ultrasonication is mainly employed to obtain PSi NPs smaller than 300 nm [112] (Figure 
9b) [109]. Moreover, the size can be highly decreased till 50 nm approximately, by 
involving high power ultrasonication (Figure 9d) [109]; (2) high shear microfluidization 
is another approach for synthesis PSi particles, however it is faster than ultrasonication, 
and can produce high yield of PSi NPs with narrow size distribution [113, 115]. PSi NPs 
are produced by both approaches; microfluidization and ultrasonication (Figure 9c) 
[109]; and (3) PSi NPs can be created through an alternative bottom-up pathway, whereas 
PSi NPs are built from silicon tetrachloride.  
 
Within this approach, a byproduct salt is formed within the produced NPs and it assist to 
form the pores through acting like a template. Afterwards, this byproduct salt is washed 
away through simple water rinsing step, leading to porous structured nanoparticles [106] 
(Figure 9e) [109]. This bottom-up strategy has the advantage of avoiding the harsh 
etchants like hydrofluoric acid. Another advantage of this bottom-up approach, is the 
possibility of adjusting the average size, pore diameters and specific surface area of the 
produced PSi NPs, as described by Fang Dai et al. [116], whereas three temperatures 
were involved within PSi NPs fabrication process: 600, 700 and 820 °C. All of these 
temperatures exhibited PSi NPs with similar mesoporous structures. However, under the 
high resolution transmission electron microscope (HR-TEM), the crystallite sizes of the 
PSi NPs were different: PSi-600 = 3-5 nm, PSi-700 = 7-10 nm and PSi-820 = 10-20 nm. 
(Figure 9f-h) [109]. Furthermore, the outcome PSi NPs from this approach presented 
higher surface area ( 580 m2/g) than those PSi NPs produced by electrochemical etching.  
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 PSi with different Surface Chemistry 
 
As mentioned before, bottom-up approaches for fabricating PSi NPs are preferred due to 
speed of the process and avoiding harsh etchants, nevertheless, electrochemical etching 
strategy is still the dominant method to produce the PSi involved in the biomedical 
applications, e.g., drug delivery systems [117, 118]. PSi recently fabricated by 
electrochemical etching possess some drawbacks which might conflict with their 
functioning upon involving in biomedical application strategies. For instance, the freshly 
fabricated PSi are extremely reactive owing to their hydride terminated surface [119], 
which makes the surface not stable chemically because the ongoing slow oxidation due 
to exposing to atmosphere air. Subsequently, this oxidation may trigger structure and 
optoelectronic alteration of PSi, in addition to possibility to react with several biological 
 
Figure 9: Fabricating PSi spherical (quasi) particles. a) The first step, etching, followed by two alternative 
techniques; ultrasonication and shearing thought micro-fluidization. b) Outcome PSi NPs contained in vials, 
micro-fluidization product (left) and ultrasonication product (right). c) TEM Images of both techniques’ PSi 
NPs product, micro-fluidization (top) and ultrasonication (down). d) TEM images of PSi NPs fabricated by 
high power ultrasonication, in two different scales: 500 nm scale bar (upper), and 100 nm scale bar (down). 
e) Illustrating diagram of the bottom-up fabrication process of PSi particles. f-h) TEM images of PSi 
particles fabricated under different temperatures; f = 600 °C, g = 700 °C, h = 820 °C. The upper images are 
produced by TEM with scale bar 20 nm, while the lower Images are produced by HR-TEM with scale bar 
5 nm.  
 
(Reference: Li, W., et al., Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy.  
Advanced Materials, 2018. 30(24): p. 1703740.) 
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materials and the loaded cargo [120]. Consequently, it is highly recommended to 
chemically modify PSi surface upon incorporating in biomedical applications, especially, 
drug delivery systems.  
 
Here, three different surface modifications are presented: thermally oxidized PSi, 
thermally carbonized PSi and undecylenic acid-modified thermally hydrocarbonized PSi. 
Direct thermal oxidation is commonly applied oxidation method for stabilizing the 
surface of PSi. In this direct oxidation process, the temperature is raised to 300-400 °C, 
whereas the oxygen bonds are built between surface Si atoms. Then, the temperature is 
escalated again to more than 600 °C, so the oxidation is boosted and all SiHx species are 
eliminated [121] (Figure 10) [109]. Nevertheless, there are other oxidation approaches, 
e.g., chemical oxidation [122], aqueous oxidation [123], photooxidation [124] and anodic 
oxidation [125]. Eliminating SixSiHy bonds and establishing OySi-OH and Si-O-Si species 
are common features among those oxidation strategies. Furthermore, it was noticed from 
experiments that these oxidation modifications alter also the properties of PSi surface 
from hydrophobic to hydrophilic [126], which may work in favor of several drug delivery 
strategies within physiological environments. 
 
Another approach for stabilizing PSi surface is thermal carbonization, which is 
categorized to two approaches according to the temperature of the process: (1) Thermally 
hydrocarbonized PSi (THCPSi), accomplished at lower temperature 400-600 °C; and (2) 
Thermally carbonized (TCPSi), accomplished at higher temperature >600 °C [104, 127, 
128] (Figure 10) [109]. In addition to stabilizing the PSi surface chemistry through this 
process, due to the comprehensive coverage of the innate silicon hydride surface, this 
process does not affect the functioning surface area of PSi [129]. Furthermore, TCPSi are 
characterized by more hydrophilic surface chemistry, which is more stable than THCPSi 
[130].  
 
Last, a PSi stabilizing and functionalizing method is used through adding some 
chemically reactive groups carboxylic acids (-COOH) and amines (-NH2), through some 
specific reactions, e.g., hydrosilylation and silanization [131] (Figure 10) [109]. From 
such reaction, undecylenic acid functionalized THCPSi (UnTHCPSi) are obtained. This 
approaches are characterized by mild procedures since the some surface alterations can 
be accomplished in room temperature [132], in addition to wide alternatives of adding 
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variant functioning reactive groups, e.g., PSi  terminated with carboxylic acid and alkenes 
[106]. 
 
Overall, these surface stabilizing approaches are conducted according to the purpose of 
use in the medical application and according to the chemical properties of the loaded 
cargo [109].  
 
 
 
 
Figure 10: Different surface modifications approaches of newly etched PSi, in order to produce 
variant PSi material with different surface chemistry, e.g., through oxidation, thermally oxidized 
TOPSi with hydrophilic surface can be produced. Thermally carbonized TC and thermally 
hydrocarbonized THCPSi can be produced through carbonization approach, which involves 
thermal decomposition of acetylene in temperature range 400-900 °C, thus TC and THC PSi are 
harvested separately in a higher and a lower temperature, respectively. Lastly, stabilizing and 
functioning PSi through hydrosilylation method using Lewis acids in presence of unsaturated 
compound, e.g., alkynes. This approach is beneficial to produce undecylenic‐acid‐modified 
thermally hydrocarbonized PSi, UnTHCPSi, with possibility to assemble different functional 
groups on the surface, e.g., alkenes and amine groups.    
 
(Reference: Li, W., et al., Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer 
Immunotherapy. Advanced Materials, 2018. 30(24): p. 1703740.) 
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 Reductive nature of PSi NPs 
 
As demonstrated earlier, the recently etched PSi possessing Si hydride surfaces exhibit 
high reductive properties, which can boost reaction with several biological material 
within the surrounding environment. During the investigation, it was found that under 
certain circumstances, PSi hydride surface is able to produce single oxygen (1O2) 
molecules that may trigger cellular toxicity. Thus, surface modifications can reduce and 
eliminate that toxicity effect, meaning better biocompatibility [133, 134].  
 
Another advantage of surface modification is controlling the biodegradation of PSi, 
which is critical element to be evaluated before incorporating in clinical applications. 
Freshly etched PSi endures quick disintegration due to surface high reactivity, therefore, 
surface modifications, e.g., oxidation and carbonization can create a protection and 
restrain this degeneration process [135, 136].  
 
There are several factors that can affect the degradation kinetics of PSi including 
temperature, pH, salinity in addition to redox environment [137]. In some studies, in vitro 
PSi degradation under influence of pH, human serum and ROS was investigated [138]. 
This study presented ROS is the most influencing factor on the PSi erosion process, since 
it can expedite the degradation significantly. Within PBS buffers with different pH (7.4 
and 6.5), PSi degradation exhibited unaffected manner, whereas PSi ML50 (which is the 
time required for half of PSi mass to degrade) [109] was approximated 7 h at either pH 
degrees. Adding human serum reduced ML50 to 6 h. On the hand, adding 2×10−3 M of 3‐
morpholinosydnonimine N‐ethylcarbamide (SIN‐1), which is usually employed to 
physiologically provoke production of peroxynitrite, an extremely ROS occurred in 
human carcinogenesis, which could dramatically reduce the PSi ML50 to 3 h.  
 
Furthermore, upon in vivo administration, it was discovered that PSi experience increased 
degradation within diseased conditions, due to presence of escalated levels of ROS, 
because of the upregulation response in the inflamed region, thus Si scaffolds are oxidized 
by ROS compounds into Si-dioxide, followed by hydrolysis of Si-O bond eventually 
leading to soluble orthosilicic acid species [110, 139], i.e., enhanced degradation process.  
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After previously mentioned surface stabilizing modifications, carbonization and 
oxidation) the PSi surface is constituted of either silicon carbide SiC or OxSiHy terminates, 
which are chemically stable, and ROS induced degeneration process correlate the 
degradation to the decomposition of the Si layer and back-bond oxidation of Si [138].  
 
Nevertheless, the ROS degradation effects on surface modified PSi are still not well 
understood and lack of investigation.   
 
 Immunogenicity and biocompatibility of PSi NPs 
 
We mentioned earlier that biomedical studies have demonstrated PSi to be competent 
apparatus for transferring therapeutics, nevertheless, nowadays there is more attention 
towards evaluating the immunogenic properties of these PSi materials [140]. Ainslie et 
al. [141] examined the immunogenic properties of several Si platforms (nanoporous, 
microstructured, nanochanneled and flat), and found that those platforms were able to 
provoke secretion of some proinflammatory cytokines by peripheral blood mononuclear 
cells (PBMCs). Likewise, other different studies have presented that PSi micro- and nano-
particles with different surface characteristics, were also able to induce distinctive 
immune reactions [142-144].  
 
The immunogenic properties of PSi NPs with different surface chemistry was 
investigated in another study by Shahbazi et al. [144], whereas other engineered PSi NPs 
were included in the study: poly(methyl vinyl ether-alt-maleic acid) conjugated 
APSTCPSi (APM), polyethyleneimine conjugated UnTHCPSi (UnP) and (3-
aminopropyl)triethoxysilane functionalized THCPSi (APSTCPSi). Human monocyte-
derived dendritic cells (DCs) were incubated with those PSi nanoparticles, in 
cytocompatible concentration 25 µg/mL. The result showed two PSi surface 
modifications (THCPSi and TOPSi) to cause high immunostimulating effect. 
Immunogenicity of THCPSi was explained according to their hydrophobicity [145, 146]. 
Meanwhile, the immunogenicity of TOPSi was attributed to immunogenic effect of the 
orthosilicic acid produced upon the degradation process of TOPSi within the 
physiological environment [144, 147] .  
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In addition, the other PSi NPs ( thermally carbonized-TCPSi, and UnTHCPSi) did not 
exhibit significant increase of the correlated co-stimulatory signals (CD80,83,86 and 
human leukocyte antigen-D related (HLA-DR)), Figures 11a and 11b [144]. 
Furthermore, THCPSi and TOPSi provoked TH1-biased immune response, recognized 
by the secretion of interleukin-12 (IL-12) and IFN‐γ, in addition to the priming CD8+ T-
cells, remarkably when incubated with TOPSi (Figures 11c and 11d) [144].  
 
 
 
 
 
 
Figure 11. Different co-stimulatory signals expressed by human monocyte derived DCs representing the 
immune response towards PSi NPs with different surface chemistry: a-b) Percentage of expressed CD80 
and CD86 after incubation with 25 µg/mL PSi NPs for 48 h. Cells were stained by specific antibodies 
against each marker and examined by flow cytometry. The outcome readings for each PSi NPs were 
compared with imDC (untreated human monocyte-derived dendritic cells (MDDCs)), which are featured 
by their negligible expression of DC maturation markers) as control. C-d) Illustration of lymphocyte 
response upon 6 days incubation with 25 µg/mL PSi NPs, showing the effect of different PSi NPs on 
inducing proliferation of CD3+, CD4+and CD8+ T cells. Most of PSi presented an immune stimulating 
effect, however, TCPSi solely did not exhibited any induction of neither CD3+ , CD4+ nor CD8+ T cells. 
TOPSi were able to induce CD8+ and CD3+ but not CD4+. UnTHCPSi exhibited only induction of CD3+. 
 
(Reference for this model: Shahbazi, M.-A., et al., Surface chemistry dependent immunostimulative potential of porous silicon 
nanoplatforms. Biomaterials, 2014. 35(33): p. 9224-9235..) 
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 Biomedical applications of PSi NPs 
 
 Drug delivery 
 
PSi possesses various features that make it an attractive apparatus for drug delivery 
approaches: the electrochemical synthesis permits building verities of controllable 
tailored pore sizes; abundant chemistries to modify PSi surfaces that can be employed to 
control the amount, type and release rate of the loaded drug; and importantly, the optical 
specifications of photonic porous Si structures which facilitates in vivo self-reporting and 
monitoring. However, there are current key challenges of drug delivery systems, e.g., 
poor solubility of drug molecules, fast clearance of drug from the body or inadequate drug 
release. Thus, PSi NPs are proposed as potential candidate to overcome this issue, i.e., to 
increase the bioavailability of the drug molecules within certain area and over defined 
time frame. Upon containing the drug cargo inside the pores of PSi, the constricted space 
of PSi NPs prevent the drug to return back into its crystalline form (lower solubility) and 
remains in amorphous form (higher solubility), meaning more control on the drug 
releasing/dissolution rate [148]. For instance, saliphenylhalamide (an antiviral drug with 
low water solubility) was loaded inside THCPSi NPs to minimize the crystalline form of 
this drug, and after applying this construction on influenza A virus infection, the results 
were very promising. Upon releasing this antiviral drug from PSi NPs, an efficient 
inhibition of influenza A infections was demonstrated in human retinal pigments 
epithelium and Madin-Darby canine kidney cells [149].  
 
PSi NPs are promising candidates for cancer drug delivery as well, especially because 
most of anti-cancer drugs are very poor water soluble. As an example of this, when 
cisplatin (anti-cancer drug) was loaded in 1,12-undecylenic acid modified PSi 
microparticles, a higher toxicity was detected than the free form of cisplatin in human 
ovarian cancer cells, due to the enhanced solubility [150].  
 
Various protein molecules can also be delivered through PSi NPs. For instance, agarose 
hydrogel matrix was used to adjust the surface of PSi particles for sustain administration 
of bovine serum albumin over long period, meanwhile maintaining the molecular 
characteristics and stability of the protein [151]. Furthermore, PSi NPs have exhibited 
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great ability to preserve the bioactive form of the protein drugs providing protection of 
the enzymatic degradation and enhance the bioavailability in targeted site [152].   
 
Therapies based on delivery of oligonucleotides have always confronted low intracellular 
delivery due to the negative charge on those oligonucleotides. Thus, PSi NPs have been 
recently proposed as efficient carrier for those therapeutics to improve cellular delivery 
and protect them against enzymatic degradation [153-155].  
 
Small interfering RNA (siRNA) molecules were loaded in PSi NPs by Wan et al. [156], 
whereas they were able to load about 7.7 µg of siRNA per mg of PSi NPs within time 
range of 30 min. Upon applying this formulation, 33% of cell apoptosis was induced 
through downregulating the corresponding mRNA and following protein expressions.  
 
All of the aforementioned applications propose PSi NPs as a potential future material for 
many drug therapies and enhanced drug delivery systems to various disease locations in 
the body.  
 
 PSi NPs as vaccine adjuvant 
  
Vaccine adjuvants are defined as molecules or compounds that possess potential 
immunomodulatory features, and when introduced conjugated to antigen, they efficiently 
improve the host antigen-specific immune response [157]. One of the main targets in 
immunotherapies is moderating the immune responses towards pathogenic incursions and 
tumors. This strategy can be accomplished through prompting immune responses through 
appropriate delivery and presenting of antigens by engineered machines, e.g., 
biodegradable NPs. Immunization can be achieved by antigen presenting cells (APCs), 
which process and present the antigen to stimulate immune response (direct approach). 
Alternatively, immune response can be provoked by transporting antigens to definite 
cellular compartments, which is followed by antigen uptake by corresponding stimulatory 
cells.  
 
To deliver those antigens, PSi NPs are proposed as potential delivery carriers. 
Researchers from University of California have designed PSi NPs as adjuvants to deliver 
antigens and stimulate prospective immune responses [158]. In this study, anti-CD40 
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antibody was bound with PSi NPs (incorporating avidin) through biotin avidin 
interaction. CD40 is a co-stimulatory protein presented on APCs and is essential for their 
activation [159]. This anti-CD40-PSi NPs combination was found to stimulate APCs 
more efficient than free anti-CD40 antibody in vitro [158]. Accordingly, a “PSi 
nanovaccine” was constructed, in which, APCs targeting protein with antigen are co-
incorporated into PSi NPs with anti-CD40 antibody. Through this PSi nanovaccine, 
immune memories can be provoked towards various antigens and multiple costimulatory 
molecules can be integrated into such nanovaccine. Furthermore, the fundamental 
photoluminescence of PS NPs enables of in vivo tracing.  
 
Nonetheless, several studies have demonstrated that such NPs-based vaccines can be 
much more efficient than soluble peptides and protein antigens solely [160, 161], and 
even more adaptable and possibly safer than viral vaccines [162-164]. 
 
 PSi NPs for biomedical imaging 
 
Bioimaging has become an essential tool for in vivo and  in vitro visualization, due to 
high sensitivity, dimensional resolution [165, 166]. Among biomedical imaging 
methodologies, PSi NPs have been given great attention due to their biocompatibility and 
intrinsic photoluminescence properties [165, 167].  
 
In a study conducted by Park et al., PSi NPs were tracked in vivo, whereas they passively 
accumulated in MDA-MB-435 human tumor. Measurements of the fluorescence intensity 
of these PSi NPs, were monitored to be decreasing correspondingly with the degradation 
of PSi NPs [167]. In another study Secret et al., showed an enhanced cell internalization 
of PSi NPs functionalized with porphyrin, whereas this construction demonstrated 3-fold 
higher internalization to MCF-7 cells when compared to free porphyrin of equal 
concentration. Furthermore, this PSi NPs-porph construct possessed efficient 
luminescence under one photon excitation [168].  
 
Additionally, the potential of PSi NPs to image cancer cells was demonstrated by 
Osminkina et al., thus PSi NPs were obtained by simple mechanical grinding of PSi 
nanowires in water. In this study, PSi NPs achieved penetration into Hep-2 (human lung 
cancer) cells without significant cytotoxicity up to 100 μg/ml. Besides, PSi NPs were 
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spotted to fulfill the cytoplasm of the cells displaying bright photoluminescence. They 
also proposed in this study, PSi NPs can be potential agents for photodynamic cancer 
therapies, since those NPs could photosensitize singlet oxygen generation [169]. Main 
advantage of PSi NPs comparing to other fluorophores is their long emission lifetime. 
Whereas, this long emission (5-13 μs) facilitates time-gated imaging in vivo. Vast 
imaging improvements were noticed upon administrating these PSi NPs intravenously 
into a mouse. Short-lived (<10 ns) emission signals due to auto-fluorescence were erased 
and background signals were strengthened >50-fold in vitro and >20-fold in vivo [170]. 
Likewise, this photoluminescence properties were enhanced when PSi NPs were 
functionalized through coating by bioresorbable polymers (polylactic-co-glycolic acid 
(PLGA) and polyvinyl alcohol (PVA), as reported by Gongalsky et al. [171]. 
 
 Other applications of PSi NPs 
 
PSi NPs are involved in many other applications due to their outstanding features. For 
instance, PSi NPs are currently involved in photodynamic therapies (PDTs) which is 
considered an efficient treatment for many diseases including cancers. In PDTs, PSi NPs 
are employed as photosensitizers, thus photoactivation with proper wavelength is applied 
to stimulate PSi NPs to transform to an excited state and transfer their energy (electron 
transfer) to the neighboring molecular oxygen, leading to production of highly cytotoxic 
singlet oxygen (1O2) and ROS. These formed 1O2 and ROS have led to death of cancer 
cells either by apoptosis or necrosis [172, 173].  
 
One more therapy using PSi NPs is thermal therapy, which use generated heat to destruct 
the cancer cells avoiding any drug resistance or genetic complications. As a result of the 
advantageous photo-thermal properties of PSi NPs, they are proposed as potential agents 
to absorb and transform photons to thermal energy, known as photothermal therapy 
(PTT). This generated heat was shown to be enough to kill 94% of cancer cells 
(T = ∼52 °C), using PSi NPs modified with DMSO to tackle nanoparticle agglomeration 
[174]. Similarly, Hong et al., proposed that PSi NPs combined with near-infrared (NIR) 
laser, were able to destroy  ∼93% of cancer cells in vitro and to remove the murine colon 
carcinoma (CT-26) tumors with almost no damage to the surrounding healthy tissue 
[175].  
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Overall, PSi NPs are very promising materials in nanomedicine and for the current and 
future scientific research. Moreover, they are becoming more widespread in various 
medical therapies and daily applications.  
 
 
1.7. Aims of the study  
 
As mentioned earlier, studies have presented that PSi particles tend to accumulate mainly 
in the liver [85, 86] upon intravenous administration. Likewise, other studies have found 
that after 4 h of blood injection with PSi, the particles were mainly localized in liver and 
spleen, while marginal accumulations were spotted in lung, heart and kidney [176, 177]. 
It was also reported previously that PSi NPs reactivity can alter within inflamed 
conditioned, e.g., ROS elevated level [138].  
 
Subsequently, in this work we aimed to investigate the behavior of PSi NPs with different 
surface chemistries, within acute liver inflammation environment, besides the effect of 
the inflammatory compounds, e.g., ROS on the degradation of PSi. Viability tests were 
also conducted to evaluate the cellular toxicity of those PSi NPs.  
 
In brief, our aims were as follow: 
 
1. To investigate the immunomodulatory effect of PSi NPs within inflammatory 
environment, by monitoring the expression of certain pro-inflammatory cytokines 
in RAW macrophages cells (in vitro), and within acute liver inflammation (ALI) 
models (in vivo), in addition to liver function assessment through liver enzymes 
analysis.  
 
2. To assess the influence of PSi NPs on ROS level within the inflammatory 
medium; intracellular ROS levels were monitored within RAW cells, as well as 
within ROS containing solution in the presence of PSi NPs. 
 
3. To examine the PSi NPs degradation rate in ROS containing medium, via 
monitoring the Si content in the medium over certain time points.  
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4. To evaluate the toxicity of those PSi NPs and their potential to recover the 
viability of HepG2 liver cells under ROS-induced apoptosis conditions.  
 
 
This study was conducted within a collaboration project, whereas the work was divided 
into two parts, in vitro and in vivo. The in vivo part, marked by (*) was conducted by our 
collaborators Yunzhan Li et al. from Xiamen University, China. 
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2. Material and methods 
 
2.1. Fabrication of PSi 
 
The involved PSi NPs were fabricated by electrochemical etching of monocrystalline 
boron-doped p+ type Si (100) wafers (Cemat Silicon S.A., Poland), whereas the same 
protocol was followed, as described in Bimbo et al. [178]. Thermally hydrocarbonized 
PSi (THCPSi) was firstly fabricated by heating at 500 °C for 15 min under 1:1 N2-
acetylene flow. Then for Un PSi production, the fabricated THCPSi films were treated in 
undecylenic acid at 120 °C for 16 h to obtain undecylenic acid-terminated carboxylic acid 
THCPSi (Un) films, as described in Jalkanen et al. [179]. Lastly, Un NPs were produced 
through wet-milling in undecylenic acid, which was centrifuged after to harvest the 
necessary size of NPs [178]. Thermally carbonized (TC) PSi NPs were fabricated by 
heating the THCPSi films absorbed with acetylene at 820 °C for 10 min, after which TC 
PSi NPs were harvested by wet ball milling in 1-decene [180]. Thermally oxidized (TO) 
PSi NPs were fabricated through placing the fresh films in atmospheric air for 2 h under 
300 °C, after which the NPs were harvested by wet ball milling the TO fabricated film in 
EtOH [181]. Eventually, all the fabricated porous silicon nanoparticles were centrifuged 
and suspended in ethanol.   
 
2.2. Characterization of PSi NPs 
 
The NPs’ size and surface zeta-potential were measured by DLS Zetasizer (Nano ZS, 
Malvern Instruments, UK), were samples were loaded in  disposable polystyrene cuvette 
(SARSTEDT AG & CO., Germany) and disposable folded capillary cells (DTS1070, 
Malvern, UK), respectively. For each PSi NP, a stock solution was prepared in PBS 20 
μg/mL, of which 20 μl was taken in 880 20 μl water for each measurement (final 
concentration of 0.4 μg/mL). Samples were sonicated before measuring and each 
measurement was done in triplicates.  
 
The porous features were studied through N2 adsorption/desorption method, and from the 
outcome data, surface area and pores characterisation of each NP was determined using 
Brunauer–Emmet–Teller and Barret–Joyner–Halenda theories [182]. Morphology of PSi 
NPs was investigated using TEM (Tecnai 12, FEI Company, USA) at acceleration voltage 
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80 kV. Lastly, surface properties and chemical modification were studied using FTIR 
with vertex 70 spectrometer (Bruker Optics, USA). 
 
2.3. Blood analyses of acute liver inflammation (ALI) models* 
 
Whole blood analysis was accomplished using an automatic biomedical analyzer 
(VetScan HM5, ABAXIS, USA), whereas manufacturers’ instructions were followed. 
Using corresponding chemical kites for analysis, serum liver enzymes (ALP, ALT and 
AST) were analyzed: ALP (140318005, Mindray, China), ALT (140118005, Mindray, 
China), AST (140218004, Mindray, China). Then samples were prepared accordingly and 
measured by an automatic biomedical analyzer (BS-240vet, Mindray, China). 
 
2.4. qPCR 
 
Two qPCR experiments were conducted in vitro and in vivo qPCR. For in vitro qPCR, 
RAW 264.7 macrophage cells were cultured in MDEM medium and seeded in 6-well 
plates of 1.5×105 cells per well, whereas each group was planned in triplicates, and 
incubated overnight. Treated with 1 μg/mL of LPS for 4 h and washed afterwards with 
1× PBS (6.7 mM, pH 7.4). PSi NPs in different concentrations were added accordingly 
and incubated for 3 h, after which the cells were washed again with PBS and harvested 
by Trypsin and total RNAs were isolated using Trizol Reagent (Magen, China).  
 
Afterwards, corresponding cDNAs were built by the TransScript One-Step gDNA 
Removal and cDNA Synthesis SuperMix (Transgen Biotech, China), whereas the 
manufacturers’ instructions were followed. cDNA  was normalized against housekeeping 
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), invariant endogenous gene 
to be used as reference gene when comparing samples together to compensate variations 
between samples. Lastly the qPCR step was conducted, thus the samples were amplified, 
and the data was analyzed through the ABI StepOnePlus Real-Time PCR System. 
The primers sequences involved in the experiment were as follow:  
TNF-α: 5' - CAG CCT CTT CTC ATT CCT GCT TGT G - 3', 5' -CTG GAA GAC TCC 
TCC CAG GTA TAT - 3'; CXCL1: 5' - AGC TTC AGG GTC AAG GCA AG - 3', 5' - 
CTG CAC CCA AAC CGA AGT - 3'; CCL2(MCP-1): 5' - AGG TGT CCC AAA GAA 
GCT GTA - 3', 5' - ATG TCT GGA CCC ATT CCT TCT - 3'; IL-6: 5' - TAG TCC TTC 
CTA CCC CAA TTT C - 3', 5' -TTG GTC CTT AGC CAC TCC TTC - 3'; IL-1β: 5' - 
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GAA ATG CCA CCT TTT GAC AG - 3', 5' - CCA CAG CCA CAA TGA GTG AT- 3'; 
GAPDH: 5' – GCC TTC CGT GTT CCT ACC C - 3' , 5' – TGC CTG CTT CAC CAC 
CTT C- 3'.  
For  in vivo qPCR, 3 h after ALI establishing, two concentrations (0.3 mg/kg or 3 mg/kg) 
of each PSi NPs were injected intravenously, and saline was injected as control. 48 h post 
administration, mice were sacrificed, and liver samples were collected and kept at −80 °C 
for further analysis. The same qPCR protocol was followed as mentioned above.   
 
2.5. ELISA 
 
An in vivo ELISA test was conducted, whereas, all the liver specimens , which were 
collected and stored at −80 °C, were prepared in ice-cold saline solution before running 
the test. The three main cytokines of interest (TNF-α, IL-6 and IL-1β) were analyzed 
within the same supernatants using the mouse ELISA kit (cat. EM001, EM004, EM008 
ExCell Biotech, China). Hence, the manufacturers’ instructions were followed, and the 
corresponding absorbance were detected by Varioskan Flash Spectral Scanning 
Multimode Reader (Thermo Fisher Scientific, USA) at 450 nm wavelength. Lastly, the 
quantities of cytokines amounts were determined on standard curves of each recombinant 
cytokine.  
 
2.6. Cell lines and culturing media 
 
Two cell lines were involved in the in vitro studies, including murine leukemia monocyte 
macrophage cell line (RAW 264.7), and human hepatocellular carcinoma cell line 
(HepG2), whereas both of them belonged to the American type culture collection, USA. 
All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, EuroClone 
S.p.A., Italy), consisting of 10% of fetal bovine serum (FBS) (Gibco, Invitrogen, USA), 
4.5 g/L glucose, 1% nonessential amino acids,  1% L-glutamine, Pencillin (100 IU/mL), 
in addition to Streptomycin (100 mg/mL), all provided by HyClone, USA.  
 
2.7. ROS consumption study 
 
Different concentrations of each PSi NPs (10, 25, 50 and 100 µg/ml) were incubated in 
PBS containing 10 mM of hydrogen peroxide H2O2 (ROS) for 24 h under orbital agitation 
at 100 rpm, after which the samples were collected and centrifuged at 15000 rpm for 5 
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min to collect the supernatant, which were transferred afterwards in 96-well plates for 
further measurements. 2´,7´-dichlorodihydrofluorescein diacetate (DCF-DA) assay was 
used to measure ROS concentration in the samples, thus 10 μM of DCF-DA was activated 
(deacetylated) by incubating with 0.1 M of sodium hydroxide (NaOH) for 30 min, and 
then added on the samples on the 96-well plate (5 μl per well), and incubated for another 
30 min.  
 
Post incubation, DCF fluorescence in the samples was detected and measured by 
Varioskan Flash Spectral Scanning Multimode Reader (Thermo Fisher Scientific, USA), 
with excitation and emission wavelengths at 498 nm and 522 nm, respectively. Each 
group was done in triplicates including negative control group (no PSi NPs). DCF-DA 
remains nonfluorescent until the acetate groups are removed by intracellular esterase 
forming dichlorofluorescein, which is oxidized in the cell by peroxide H2O2 to form DCF 
fluorophore. This hydrolysis can be achieved also with NaOH. Eventually the 
fluorescence is measured by Varioskan.   
 
2.8. In vitro ROS consumption 
 
RAW 264.7 macrophage cells were seeded in MDEM medium in 12 well plate (5×105 
cells per well) and kept overnight. The experiment is designed in two sets, thus in the first 
set, proinflammatory intracellular ROS production was stimulated by incubating  the cells 
with 10 pg/mL of IFN-γ and 1 μg/mL of LPS for 4 h, after which the cells were washed 
by 1× PBS (6.7 mM, pH 7.4) to remove the traces of IFN-γ and LPS and stop their 
stimulation. The second set was kept without IFN-γ and LPS treatment.  
 
Two control groups were established: blank cells and cells treated with 1 μg/mL of LPS. 
Then, all the cells were treated by 10 μM of DCFH-DA (0.5 mL per well) and incubated 
for 1 h. Afterwards, the excess of DCFH-DA was washed away through washing the cells 
3 times by 1× PBS which also assure eliminating any possible traces of DCFH-DA, LPS 
or IFN-γ, which may affect the result.  
 
Then PSi NPs were added to the cells in different concentrations (2, 10, 20 and 50 μg/mL) 
and incubated overnight. Afterwards, cells were detached and collected by 1× trypsin (0.5 
ml per well), then cells were fixed in 4% of paraffinaldehyde in 1× PBS for 15 min , after 
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which the cells were washed by 1×PBS and stored in 4 °C for later measurement. ROS 
level was measured by LSR II flow cytometer (BD Biosciences, USA), using laser 
excitation wavelength of 488 nm and the experiment was run by FACS Diva software, 
whereas minimum of 5000 events were collected. Manufacturers’ instructions were 
followed for the FACS protocol. All the groups were planned on the 12 well plates in 
triplicates.  
 
2.9. HepG2 cells viability 
 
Cell viability study was conducted in two groups, whereas the first group contained 
HepG2 cells cultured in MDEM medium containing different concentrations of H2O2 (0–
2 mM), in addition to 50 μg/mL of each PSi NPs. The second group comprised HepG2 
cells cultured in 0, 0.8, 1, 1.6 and 2 mM of H2O2  containing DMEM medium that was 
preincubated with 50 μg/mL of each PSi NPs for 24 h before introducing to the cells. 
Control sets were composed of solely HepG2 cells in DMED medium. 
 
Both groups were incubated for 24 h, after which their cellular viabilities were measured 
via an ATP-luminescence assay (CellTiter-Glo® Luminescent Cell Viability Assay, 
Promega, USA). Manufacturer’s instructions were followed, and the luminescence was 
detected by Varioskan Flash Spectral Scanning Multimode Reader (Thermo Fisher 
Scientific, USA).  
 
 
2.10. PSi degradation in ROS containing medium 
 
The experiment was designed in two groups, whereas in each group, 150 µg of each PSi 
NPs were incubated in 3 mL degradation medium which is composed of 1× PBS (6.7 
mM, pH 7.4) containing 1% of poloxamer 188 (p188). 2 mM of 3-
morpholinosydnonimine (SIN-1, Enzo Life Sciences, USA) was added to one of the two 
groups as ROS source, meanwhile the other group was maintained SIN-1 free.  
 
Both groups were kept on orbital agitation of 100 rpm at 37 °C for 10 days, during which 
samples were collected at certain time points, and pH was monitored thoroughly. 
Collecting samples was performed by taking 1.2 mL of each 3 mL falcon tube to an 
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Eppendorf (A), then centrifuging at 13200-15000 rpm for 8 min. 1 mL of transparent 
supernatant was collected in another Eppendorf (B), which was filtered to a new falcon 
tube marked with the time point, and 4 mL of 5% nitric acid was added. Falcons 
containing filtered samples were sealed properly and stored at 4 °C for further 
measurements. 1 mL of fresh degradation medium (pre-prepared and stored in the fridge) 
was added to the pellet in Eppendorf A, and sonicated to recover the 1.2 mL amount. This 
particle solution in Eppendorf A was returned to the main falcon tubes, thus 3 mL volume 
in the main PSi NP falcon was maintained through the whole experiment. Control groups 
were set as total degradation samples of PSi NPs which were constituted by incubating 
PSi in NaOH solution. Eventually, all samples were measured for total Si contents by 
microwave plasma atomic emission spectroscopy (MP-AES, Varian Inc. Santa Clara, 
CA, USA). 
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3. Results  
 
3.1. Characterization of PSi NPs 
 
Three types of PSi NPs, representing the mainly applied PSi surface stabilization 
methods, with different surface chemistry, i.e., thermally oxidized PSi NPs (TO), 
thermally carbonized PSi NPs (TC) and undecylenic acid modified thermal 
hydrocarbonized PSi NPs (Un), were included in the current study and their 
physiochemical characterization were correspondingly investigated. TEM was first 
applied to observe the morphology of these different PSi NPs (Figure 12a).  
The hydrodynamic size and surface zeta-potential of different NPs were studied via 
dynamic light scattering (DLS) coupled zeta-potential analyzer. However, pore volume 
and pore size were studied via N2 adsorption/desorption method, thus depending on the 
outcome data using Brunauer–Emmet–Teller and Barret–Joyner–Halenda theories, the 
specific surface area and pores characteristics were evaluated (Figure 12b).   
 
Later, Fourier transform infrared spectroscopy (FTIR) was conducted to confirm the 
distinctive surface characteristics of those NPs. The FTIR results demonstrated 
distinguishable bands identified at 882 and 3740 cm-1, which were attributed to -OySi-Hx 
and Si-OH bonds respectively. At 1715 cm-1, both Un and TO NPs showed the ν (C=O) 
band. Whilst, for Un NPs this band was identified as confirmation of successful 
undecylenic acid hydrosilylation. Meanwhile, for TC NPs, this band was attributed to the 
acetylene treatment and the subsequent high annealing temperature. At 1630 cm-1 , TO, 
TC and Un NPs exhibited variant hydrophobicity from this water related band, whereas 
it was more preeminent with TO and TC (Figure 12c). Although the different surface 
stabilizations methods executed on PSi NPs, there were hydrides remains (-OySi-Hx)  
detected on the surface of PSi within PSi hydride stretches area  between 2100 – 2300  
cm-1. Despite the different surface chemistry [183], these PSi NPs shared a similar particle 
size, porosity and zeta-potential Table 2. 
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Table 2: Characterization of PSi NPs, revealed the similarity between the three PSi NPs; TO, TC and Un, 
whereas they shared relatively similar particles sizes, porosity and δ-surface potential. 
 
 
 
 
 TO TC Un 
Size (nm) 175 ± 15 154 ± 5 180 ± 6 
δ-potential (mV) -26 ± 2 -25 ± 5 -30 ± 1 
Specific surface area (m2/g) 203 ± 11 212 ± 4 242 ± 1 
Total pore volume (cm-3/g) 0.57 ± 0.04 0.52 ± 0.07 0.73 ± 0.01 
Pore diameter (nm) 11.3 ± 0.2 9.9 ± 1.4 12.0 ± 0.1 
Figure 12: Physicochemical characterization of PSi NPs exhibiting the specific features of each NP, 
in addition to graphic illustration of their distinguished surface chemistry; thus, the morphological 
topographies were examined under TEM, and the result showed a great similarity in the outer 
appearance and diameter (a). The porous properties were examined by N2 adsorption/desorption 
method, which revealed UnPSi to possess the highest pore volume (b). surface chemistry properties 
were examined by FTIR, which demonstrated the different surface chemical compositions of those PSi 
NPs (c). 
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3.2. Immunomodulatory influences of PSi NPs  
 
As explained earlier, PSi NPs tended to accumulate in the liver predominantly, when 
injected intravenously. Besides, they also were found to exhibit altered behaviors from 
the inflamed environment to the healthy one. Thus, according to our goals in this study 
to assess the immunomodulatory effects of PSi NPs within inflammatory conditions, it 
was essential to induce an acute liver inflammation in mice ahead of the protocol.  
 
 PSi NPs within acute liver inflammation (ALI) model* 
 
Acetaminophen (APAP) was administrated in a high dose to induce the acute liver 
inflammation (ALI) in the mice. APAP was reported to induce hepatocellular necrosis in 
1.5 h when administrated in high dose [184]. Three hours following the induction, PSi 
NPs (TO, TC and Un) were introduced to ALI mice, intravenously. Each of those NPs 
was administrated in two concentrations, low (L) = 0.3 mg/kg and high (H) = 3 mg/kg, 
and saline was considered as control, whereas each group composed of 5 mice. Two 
groups (healthy and ALI) were left without NPs injection, which were indicated as 
healthy and ALI groups. After 48 h of the administration, blood samples were collected 
from all the groups, for further analyses.  
 
Whole blood analyses were conducted to estimate the immunological effects of these PSi 
NPs and the success of establishing the ALI models, represented in the total number of 
the white blood cells (WBCs). The result showed that ALI groups exhibited a statistically 
significant (p = 0.013) increase in WBCs level, when compared with the healthy groups, 
which is a confirmatory sign of establishing the ALI model [185]. Nevertheless, there 
was no further significant increase of WBCs triggered by introduced PSi NPs, when 
compared with ALI group. Thus, introducing either of these PSi NPs did not promote any 
further inflammatory effect. 
 
Afterwards, the compositions of WBCs in the blood were analyzed in all of the groups, 
meaning; the ratio of the main three WBCs types: Granulocytes (GRA), Figure 13b; 
Monocytes (MON), Figure 13c; and Lymphocytes (LYM), Figure 13d. Likewise, the 
outcome showed that administration of any of these PSi NPs did not exhibit any further 
alteration of the overall composition of WBCs, upon with the ALI group. This reading 
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endorses the insignificant effect of these PSi NPs on the immune system in either healthy 
or inflamed environments.  
 
Afterwards, the influence of PSi NPs on liver functions was examined through serum 
analysis. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline 
phosphatase (ALP) is defined as universal indicators for the liver functions [186], thus 
the measurements of those enzymes were analyzed to assess the progression of the 
consequent hepatocellular necrosis. From the result, it was distinguished that PSi NPs had 
a burlier influence on AST than ALT. Except of TC H group, AST level were declined 
with most of the introduced PSi NPs, while a limited effect was noticed on ALT level 
comparing to ALI group Figures 13f and 13e, concluding that most of PSi NPs led to 
reduced AST/ALT value, of which, Un H group presented the most statistically 
significant decrease (Figure 13g). Likewise, Un H group showed a similar decreasing 
effect on ALP value when compared to ALI group (Figure 13h). This distinguished 
decline in AST/ALT and ALP level, can be translated as indicators for improving 
inflammation conditions and liver necrosis mend [187].  
 
Glutathione (GSH) is an important antioxidant whose deficiency has been attributed to 
liver malfunction [188]. Therefore, GSH level was further analyzed as confirmatory 
assessment of the effect of PSi NPs on the ALI mice. Captivatingly, ALI mice showed 
improved GSH level after administrating TO H and Un H groups (Figure 13i), (p = 0.032 
for TO H and p = 0.019 for Un H. 
 
Collectively, the enhanced values of AST/ALT, ALT and GSH in ALI group may refer 
to potential ability of PSi NPs to mitigate the inflammation conditions.  
 
 In vitro and in vivo* effects of PSi NPs on the proinflammatory 
cytokines 
 
Under pathological circumstances, the inflammation is accompanied by elevated values 
of the proinflammatory cytokines, which can induce perilous consequences [189]. And 
since PSi NPs showed enhancing effect on liver function, it is beneficial to evaluate the 
immunomodulatory effect of those NPs and their influence on the proinflammatory 
cytokines. Therefore an in vivo study was resumed to assess the immunomodulatory 
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effect of these PSi NPs, utilizing quantitative real-time polymerase reaction (qPCR) to 
quantitively analyze mRNA level of those corresponding proinflammatory cytokines 
within samples from both healthy and ALI groups, in order to evaluate the inflammatory 
progression after injecting the PSi NPs. In order to conduct qPCR, corresponding primers 
of each cytokine were engaged to construct and amplify the consequent cDNA strands. 
 
The main emphasized cytokines analyzed in this in vivo study are: interleukin 1 beta (IL-
1β), Interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), chemokine (C-X-C motif), 
ligand 1 (CXCL-1), chemokine (C-C motif) and ligand 2 (CCL-2). 
 
The result proposed that mice in ALI group demonstrated elevated values: 3.3-folds, 2.7-
folds, 2.9-folds, 2.8-folds and 4.9-folds of TNF-α, IL-6, IL-1β, CCL-2 and CXCL-1, 
respectively, comparing to healthy mice. Remarkably, administrating PSi NPs exhibited 
surface chemistry reliant immunoregulatory effect on ALI mice, however, TO H and Un 
H exhibited dramatically decreased level of TNF-α and IL-6 expression, in addition to 
lower IL-1β expression in Un H as well. Again, both of TC groups did not present any 
significant variation (Figure 14a).  
 
This was followed up by an enzyme linked immunosorbent assay (ELISA) to quantitively 
measure these three cytokines (TNF-α, IL-6 and IL-1β) in the liver. ALI mice exhibited 
escalated amount (3.2-folds, 1.3-folds and 1.4-folds) of TNF-α, IL-6 and IL-1β, 
respectively, when compared to healthy group. However, TO and Un reduced the amount 
of these proinflammatory cytokines in concentration related approach. Regarding TC 
groups, an indistinct effect was observed, whereas at TC low concentration, IL-1β amount 
was slightly decreased, meanwhile at TC high concentration, TNF-α amount was mildly 
decreased (Figure 14b-d). These immunomodulatory effect on the proinflammatory 
cytokines, after PSi NPs administration, may explain the inflammation enhancements and 
relieving effect of PSi NPs. 
 
Next, in vitro study was conducted to confirm the obtained in vivo results, whereas 
capability of PSi NPs was examined to induce production of any proinflammatory 
cytokines when administrated solely to healthy lab cultured macrophages. Therefore, 
Murine macrophage cell line RAW 264.7 were cultured overnight in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% of healthy mice plasma (further 
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referred as healthy medium). Cells were treated with 1 μg/mL of LPS for 4 h, to activate 
those macrophages to express the cytokines of interest, and two control groups were set; 
positive control, and negative control, which was treated only with DMEM medium 
without PSi NPs. Afterwards, the cells were washed by PBS and PSi NPs were added in 
the two concentration: low = 2 μg/mL and high 20 μg/mL. Finally, the mRNA was 
extracted, and qPCR was conducted to evaluate the cytokines expression in the cells. 
Thus, the corresponding primers of the cytokines were employed to construct and amplify 
the consequent cDNA strands. 
 
The result suggested that most of introduced PSi NPs did not significantly provoke any 
further cytokines production except TO (high concentration), which slightly activated 
RAW macrophages (Figure 15).  
 
This result suggested the biocompatibility of most of administrated PSi NPs and their 
diminutive influence to induce potential immune-inflammatory response, which 
encourages additional studies to further understand PSi NPs reactivity and behavior 
within biological environment.  
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Figure 13: The altered physiology of diseased liver after in vivo administrating PSi NPs. Upon 
establishing ALI model by APAP and administrating different concentrations of PSi NPs 3 h after 
(L = 0.3 mg/kg, H= 3 mg/kg), a whole blood analysis was conducted after 48 h for reviewing the 
biological changes within the ALI models. The outcome results proposed the following potential 
events: (a) WBCs number in ALI model was not significantly affected by administration of PSi NPs, 
neither the composition of the main WBCs types; granulocytes (b), monocytes (c) and lymphocytes 
(d) with exception of TO NPs (h), which exhibited slightly increase of GRA and MON. For Liver  
enzymes’ analysis, administration of PSi NPs did not affect ALT values (e) but decreased AST 
significantly (f), i.e., TO H (p = 0.0124), TO L (p=0.0019), TC L (p = 0.0020), Un H (p < 0.0001) 
and Un L (p = 0.027). These changes were concluded in altered AST/ALT value, subsequently, with 
Un H reaching statistical significance of p= 0.038 (g). Likewise, Un H group exhibited significant 
decrease of ALP (p= 0.0070) (i). lastly, GSH value was noticeably enhanced within TO H (p=0.032) 
and Un H (p=0.019) groups.  
 
The data on the graphs are plotted as mean ± SD obtained from 5 neutral duplicates, *p < 0.05, **p 
< 0.01, ***p < 0.0005 and ****p < 0.0001 correlated to ALI model (two-tailed Student’s t-test). 
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Figure 14. In vivo immune response in ALI models upon administrating PSi NPs. After establishing 
ALI model and introducing PSi NPs, as mentioned in Figure 13, mRNAs of proinflammatory cytokines 
were detected by qPCR (a), whereas mRNA level of each cytokine from healthy mice was set at 1. 
Comparing to ALI, group, TNF-α and IL-6 expressions were decreased in both groups TO H (TNF-α, 
p = 0.0048 - IL-6, p = 0.0096),  and Un H ( TNF-α, p < 0.0001- IL-6, p = p = 0.044). In addition to 
dropped expression of IL-1β in Un H group (p = 0.0025). 
This qPCR was followed by ELISA for quantification of these cytokines, whereas more precise effects 
were detected. (b) TNF-α expression was significantly inhibited by PSi NPs when compared to ALI 
group; TO H (p = 0.004), Un H (p < 0.0001), Un L (p = 0.0031), TC H (p = 0.025), TO L (p = 0.0083). 
(c) likewise, IL-6 expression was affected by introducing PSi NPs, whereas comparing to ALI groups, 
the expression levels were less in TO H (p = 0.0019), Un H (p = 0.020), Un L (p = 0.0019), TO L (p = 
0.029) groups. (d) PSi NPs effect on IL-1β expression, was monitored , thus TO H exhibited the greatest 
reducing effect (p < 0.0001), followed by Un H (p = 0.033) and TC L (p = 0.041).  
 
- The data on the graphs are plotted as mean ± SD obtained from 5 neutral duplicates, *p < 0.05, **p < 
0.01, ***p < 0.0005 and ****p < 0.0001 correlated to ALI model ( two-tailed Student’s t-test). 
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3.3. PSi NPs modulation effect on intracellular ROS  
 
As explained earlier that ROS compounds are critical co-inflammatory product that 
provoke further damage and even cell death eventually, in addition to reported 
mitochondria damage vastly correlated to escalated generation of ROS [190]. AST 
increasing level upon creating ALI model, may be considered a strong proof of 
mitochondrial damage, based on fact that AST predominantly exist in the mitochondria. 
Hence, ROS is another crucial prospective to investigate within the inflammation 
environment. Moreover, several previous studies have demonstrated the chemical 
reactivity of PSi material with ROS due to the reductive nature of PSi. Notwithstanding 
the surface stabilization modifications, the main structure of PSi NPs backbone is 
remained composed of Si-Si bonds which tend to react with ROS compound, within an 
oxidation reaction, to build Si-O-Si bonds which assist the hydrolysis  and depletion of 
the PSi NPs (Figure 16a) [138]. Thus, it is anticipated that administration of PSi NPs 
may have some potential influence on the ROS level which may relief the oxidative stress 
and mitigate inflammation, eventually.  
 
Figure 15. In vitro qPCR revealing the immunomodulatory effects on inflamed 
macrophages upon introducing PSi NPs. Inflammation was provoked in RAW cells with 
1 μg/mL LPS for 4 h, after which PSi NPs (L = 2 μg/mL and H = 20 μg/mL) were introduced. 
The qPCR results proposed the PSi NPs to possess relatively neutral immuno-effect, whereas 
most of the cytokines were not significantly further induced by introducing PSi NPs. 
Nevertheless, some PSi NPs reduced some cytokines expressions, e.g., Un H decreased IL-
1β, IL-6 and CCL-2. 
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Firstly, we assessed the PSi NPs capability to consume ROS due to the prementioned 
reactivity. Therefore, PSi NPs in different concentrations were incubated with ROS 
(H2O2) overnight, after which the ROS levels in the media were measured (Figure 16e).  
 
The result demonstrated that ROS consumption occurred in concentration dependent 
routine. TO has expressed the highest consuming capability while Un had minor effect, 
and TC was located between TO and Un. We suggested this phenomenon has happened 
in such manner, due to the different surface chemistry of these three PSi NPs that can 
affect the hydrophilicity of this NPs to the watery incubation solution, which obviously 
can restrain the reactivity [191]. Subsequently, this was confirmed by wetting contact 
angle (WCA) study, by installing a 5 μL water droplet on glass slide enclosed by dried 
PSi NPs film. After this, the contact angle between the water drop and PSi NPS films was 
examined with attension theta optical tensiometer. Unsurprisingly, TO has exhibited the 
highest hydrophilicity, meanwhile Un showed the lowest: TO 51° ± 5°, TC 62° ± 4° and 
Un 122° ± 6° (Figure 17).   
 
Thereafter, in vitro study was established to evaluate the effect of  PSi NPs on intracellular 
ROS of cultured Murine macrophages RAW 264.7. ROS level was monitored under both 
healthy and inflammatory conditions, whereas LPS and interferon γ (IFN-γ) were 
introduced to RAW cells to activate/induce inflammation. ROS levels was detected by 
2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence assay [192]. Upon 
introducing TO, TC and Un PSi NPs to healthy RAW cells, there was no influence 
recorded on the intracellular ROS, regardless of PSi NPs concentrations (Figure 16c). 
This result was confirmed from previous study that demonstrated PSi NPs scarcely 
elevated the intracellular ROS level within macrophages, under healthy conditions [192]. 
However, under inflammatory conditions and elevated  proinflammatory ROS production 
within RAW macrophages (above 2-fold), because of adding LPS and IFN-γ, 
administrating PSi NPs did not present distinguished effect on intracellular ROS, neither 
further increasing nor decreasing (Figure 16d).  
 
Remarkably, this result revealed the restricted influence of PSi NPs on the intracellular 
ROS within cellular environment. However, this needed to be confirmed by viability test 
to investigate any interfering influence of PSi NPs on the cellular viability, which may 
impact the overall intracellular ROS level.  
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3.4. Cellular viability reverse effects by PSi 
 
The preceding experiment was followed by this study to assess the ability of PSi NPs to 
prevent cell apoptosis provoked by ROS (H2O2). HepG2 liver carcinoma cells were 
cultured and incubated with different concentrations of H2O2, in addition to 50 μg/mL of 
each PSi NPs type, for 24 h. Upon examining the cell viability after 24 h, no enhancement 
on cell viability was observed (Figures 17g and 17h). However, when PSi NPs were 
incubated with H2O2 for 24 h before administrating to HepG2 cells, only TO PSi NPs 
were observed to slightly mitigate the toxicity of H2O2 and recover ROS induced cellular 
apoptosis (Figure 16f). This phenomenon can propose that H2O2 provoked cellular 
apoptosis occurred in faster rhythm than ROS consumption by PSi NPs, which 
corresponds to the result concluded from previous study by Liu et al. [193].  
 
The overall result refers to the in vitro limited effect of PSi NPs to consume ROS within 
cellular conditions, thus failing to mitigate the inflammatory condition. In addition, it 
demonstrates the biocompatibility of those PSi NPs, which did not exhibit any significant 
cellular toxicity.  
 
Nevertheless, these PSi NPs are influenced by ROS within oxidation reaction in favor of 
enhanced degradation. For further understanding of this ROS induced PSi NPs 
degradation, we conducted the following degradation experiment. 
 
3.5. Effect of ROS in modulating PSi degradation  
 
As explained earlier, one of the preferred characteristics of the biomaterial is to be 
degradable and eradicable from the biological system after their function is accomplished, 
because it has been found in previous studies that prolongated incubation time of the 
biomaterial may consequence into long-lasting inflammation [109, 138]. Moreover, the 
microenvironment surrounding the NPs may have an effect on their degradation manner, 
which has been presented in some publications that under inflammatory conditions, the 
microenvironment exhibited an expediting influence on the in vivo degradation 
demeanour of PSi microparticles [138]. Subsequently, here we investigated the influence 
of the proinflammatory ROS compounds, which occur abundantly within the inflamed 
area, on PSi NPs degradation routine. Thus, we incubated H2O2, as ROS source, with 
different concentrations of the three PSi NPs particles; TO, TC and Un, whereas ROS 
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concentration was monitored periodically, through 2´,7´-dichlorodihydrofluorescein 
diacetate (DCF-DA) fluorescence assay. 
 
Interestingly, ROS concentration and PSi NPs concentrations exhibited inverse 
proportionality relationship, whereas ROS concentration was decreasing correspondingly 
with the increase of PSi NPs concentration (Figure 16e). More precisely, TO PSi NPs 
displayed the most capability to consume ROS, meanwhile, the effect of Un PSi NPs was 
scarcely noticed. TC PSi NPs came between TO and Un to affect ROS concentration.  
 
This result can be attributed to the contrasting surface chemistry of these PSi NPs, which 
conflicts with surface wetting procedure, because TC and Un possess hydrophobic 
surfaces, as exhibited earlier in the previous FTIR study and WCA study (Figures 12c 
and 16), respectively.  
 
This study was followed by measuring the degradation manner of those PSi NPs in 
presence and absence of different ROS (3-morpholinosydnonimine (SIN-1)). Samples 
were collected frequently based on specific timeline and total Si-content was analyzed in 
each sample by microwave plasma atomic emission spectroscopy.  
 
Similarly, the degradation rate was noticeably increased in presence of ROS in varied 
magnitudes (Figure 16b), and TO showed an accelerated degradation rate when ROS 
added, whereas the effect was noticed during the first 6h of incubation. In addition, it took 
longer time for TC and Un to show enhanced degradation with ROS, whereas the effect 
on TC was not observable until the second day, meanwhile Un showed a boosted 
degradation only after 7 days. 
 
This behavior reconfirms that different surface chemistry of these PSi NPs, as well as the 
hydrophobicity may limit the reactivity of ROS with the silicon bonds. ROS can 
accelerate the degradation of PSi NPs through oxidizing the Silicon bonds (Si-Si), 
however, the time required to expose these silicon bonds is highly dependent on the 
variant surface chemistry and hydrophobicity of these particles.  
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Figure 16. ROS compounds are inflammation co-product causing an oxidative stress and chemically it 
tends to react with PSi NPs, more specifically with the Si-Si bonds, in an oxidation reaction. This 
reaction results into Si-O-Si forms which is more degradable in presence of H2O (a). PSi NPs occurring 
in ROS containing medium would exhibit an accelerated degradation (b) due to the previous mentioned 
reaction. Whereas upon incubating 50 μg/mL of  PSi NPs in PBS medium containing ROS source (2 mM 
of SIN-1), this phenomenon was more noticeable with TO and TC than Un, which is attributed to the 
variant surface chemistry of those PSi NPs.  
This was followed by another study to evaluate PSi NPs effect on ROS compounds within intracellular 
environment, thus PSi NPs (2-50 μg/mL) were incubated for 24 h with two sets of RAW cells, (c) healthy 
RAW set and (d) inflamed RAW cells set (inflammation was established through incubating cells with 
1 μg/mL of LPS and 10 pg/mL of IFN-γ for 4 h). Nevertheless, two control groups were maintained for 
both sets; negative control and positive control (LPS 1 μg/mL). When intracellular ROS levels were 
monitored in both sets, PSi NPs did not exhibit any significant effect of ROS level in either healthy or 
inflamed RAW cells. 
(e) ROS consuming properties was examined through incubating different concentrations of PSi NPs (2-
50 μg/mL with 1 mM of H2O2 for 24 h, after which, the remaining ROS concentration was determined 
by DCFH-DA assay. The result proposed TO PSi to have the strongest ROS consuming effect followed 
by TC and Un. However, the ROS consumption occurred in a concentration dependent manner.  
(f) PSi NPs were tested for their ability to recover cell viability and reverse ROS induced apoptosis, thus 
HepG2 cell line was involved. PSi NPs (50 μg/mL) were incubated in H2O2 containing DMEM medium 
(0-2 mM ) for 24 h before introducing to HepG2 cells. TO PSi NPs exhibited a potential effect to recover 
the cellular viability. Nevertheless, when same experiment was conducted without preincubation of PSi 
NPs with H2O2, there was no significant recovery effect recorded on cellular viability when after 
introducing PSi NPs (g,h).  
 
The data on the graphs are plotted as mean ± SD obtained from 3 duplicates, *p < 0.05, **p < 0.01, ***p 
< 0.0005 and ****p < 0.0001 correlated to ALI model (two-tailed Student’s t-test). 
 
 
Figure 17. Evaluating the WCA of the involved PSi NPs (TO, TC and Un). Un exhibited the 
highest hydrophobicity, while TO demonstrated the highest hydrophilicity. TO 51° ± 5°, TC 
62° ± 4° and Un 122° ± 6°. 
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4. Discussion  
 
Nowadays, PSi materials are widely abundant within biomedical applications for various 
purposes, including drug delivery, diagnostics and immunotherapy, due to their high 
biodegradability in the physiological environment and effortless modifications of their 
physicochemical and biophysical properties. Nevertheless, further researches are still 
required for better understanding about the reactivity of these materials with the body 
biology.  
 
As demonstrated earlier, immune responses to NPs may highly depend on protein corona 
accumulated around the NPs’ core [69, 77-82]. However, in this study we have 
investigated the consequential events occur upon introducing those NPs to the body, 
during a nanomedical therapy, for instance, rather than examining the structure of protein 
corona. And since the liver is a main ultimate harbor for NPs accumulation, it was 
considered to be a suitable example to study the in vivo alterations arisen upon 
administrating NPs.  
 
Firstly, the three surface chemistries modified PSi NPs were characterized and their 
surfaces were distinguished to assure the surface chemistry modifications, as well as the 
physicochemical properties. Whereas, they all exhibited similar particle size, porosity and 
zeta-potential, nevertheless, FTIR result demonstrated their distinctive surface chemistry.  
 
When investigating liver functions after introducing the PSi NPs, Un and TO PSi NPs 
presented a promising aptitude to improve inflammation conditions of necrosing liver, 
which was recognized by improved AST/ALT and GSH values. Moreover, those PSi NPs 
did not provoke any significant immune response whereas the WBCs level and 
compositions was not altered after introducing the PSi NPs.  
 
Nevertheless, it has been insinuated in earlier studies, that Un PSi NPs exhibited a slight 
toxicity on the liver when administrated under normal physiological circumstances, 
because it was accompanied by diminutive increase in serum lactate dehydrogenase 
(LDH) and AST levels. Meanwhile, TO and TC PSi NPs revealed satiated 
biocompatibility under same conditions  [192, 194]. In addition, in the current study we 
demonstrated that these three PSi NPs did not stimulate any further hepatic inflammation 
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when administrated under ALI conditions, and that TO and Un exhibited aptitude to 
mitigate the liver injury. Both results together can be concluded that PSi NPs behave 
differently under ALI conditions when compared to normal states, and this behavior can 
be attributed to the variant surface features of the PSi NPs.  
 
Similarly, in vivo results showed TO and Un PSi NPs were able to decrease inflammatory 
cytokines; decreased level of TNF-α and IL-6 expression in TO H and Un H groups, and 
dropped IL-1β expression in Un H. Moreover, those PSi NPs did not provoke significant 
cytokines production when introduced to RAW cells in vitro, with exception of TO H, 
where macrophages were slightly activated. Interestingly, these results may match with 
some previous studies presented that oxidized PSi NPs (e.g., TO) had a provoking effect 
on the immune system, whereas they were able to activate the maturations of the DCs and 
assisted proliferation and differentiation of lymphocytes. In addition, TC and Un had a 
very limited effect on the immune response [142, 144]. Nevertheless, this can be 
attributed to the fluctuating behavior of those NPs that can vary within the same 
inflammatory environment that rises to different biological outcome.  
 
Even though, TO and Un PSi NPs have exhibited a denoted effect on proinflammatory 
cytokines, none of the PSi NPs have demonstrated a significant effect on intracellular 
proinflammatory ROS. Nevertheless, the interaction between Si-Si bonds, in the PSi NPs 
backbones, and ROS compounds was confirmed. Furthermore, ROS consumption has 
been demonstrated to improve the degradation process of PSi NPs dramatically, TO in 
particular. However, these phenomena were not of much efficiency in vitro.  
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5. Conclusions 
 
In this study, the biological influence of variant surface chemistries of PSi NPs was 
demonstrated on several perspectives, i.e., immune response, inflammatory mitigation 
and cellular interaction. Besides, the effect of the surrounding environment on the 
behavior of PSi NPs, e.g., degradation.  
 
Although, minor immune responses were detected, those investigated PSi NPs did not 
demonstrate significant cellular toxicity, but exhibited a promising potential to improve 
and attenuate the inflammatory conditions. Furthermore, these PSi NPs exhibited a 
potential consumption capacity of proinflammatory ROS compounds, which were founds 
to boost the degradation process of PSi NPs, proposing an improved biodegradability and 
clearance. 
 
Nevertheless, there is more investigations required to further understand the mechanisms 
and reactions of these PSi NPs and the functionality of their protein corona within cellular 
environment.  
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